ArticleDrug design, development and therapy2026
Artesunate Targets MBL2 to Modulate the TLR4/NRF2/HO‑1 Axis and Ameliorate Podophyllotoxin‑Induced Liver Injury.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Drug-induced liver injury (DILI) presents a significant clinical challenge with limited preventive and therapeutic options. Artesunate (ART) holds potential for DILI treatment; however, its precise hepatoprotective mechanisms and direct molecular target(s) remain unclear. Methods: We evaluated ART in a podophyllotoxin (PPT)-induced rat model of DILI. Its direct target was identified through integrated chemical proteomics (pull-down/LC-MS/MS) followed by biophysical validation (SPR, MST) and molecular dynamics simulations. Mechanistic insights from hepatic transcriptomics (RNA-seq) were confirmed by Western blot, and extended with targeted metabolomics and 16S rRNA sequencing of gut microbiota. Results: ART administration conferred significant hepatoprotection in the PPT-induced rat model, as evidenced by dose-dependent amelioration of key serum markers of liver injury (P < 0.05), attenuation of hepatic oxidative stress, and improved histopathological outcomes. Mechanistically, we identified mannose-binding lectin 2 (MBL2) as a direct, high-affinity target of ART (KD ≈ 3.84 µM). Upon binding to MBL2, ART suppressed the hepatic TLR4/NF-κB inflammatory axis and, in parallel, relieved NF-κB-mediated repression of NRF2, thereby cooperatively activating the NRF2-driven antioxidant defense program. Integrated multi-omics analysis further revealed that ART remodeled the gut microbiota, enriching beneficial genera including Lactobacillus, and that the abundance of these bacteria correlated positively with hepatic levels of antioxidant metabolites (P < 0.05), supporting a functional role of the gut-liver axis in its systemic protective effects. Conclusion: This study elucidates that ART alleviates DILI through targeting MBL2, thereby dually modulating the NF-κB/NRF2 signaling axis to simultaneously suppress inflammatory responses and enhance endogenous antioxidant defenses. These findings provide a novel and robust pharmacological basis for repositioning ART for the clinical prevention and treatment of DILI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.